Trametinib Products | Cleanchem - A targeted therapy used in the treatment of melanoma and other cancers with specific mutations in the BRAF gene. It inhibits MEK1 and MEK2, key proteins in the MAPK/ERK pathway, which helps to prevent cancer cell growth and survival.

N-Nitroso Trametinib Impurity 1

Cat. No: CL-TMTB-NO-01

CAS No: NA

Mol. F: C26H22FIN6O5

Mol. Wt: 644.39

Inv. Status: Custom Synthesis

N-Nitroso Trametinib Impurity 2

Cat. No: CL-TMTB-NO-02

CAS No: NA

Mol. F: C25H22FIN6O4

Mol. Wt: 616.38

Inv. Status: Custom Synthesis

N-Nitroso Trametinib Impurity 3

Cat. No: CL-TMTB-NO-03

CAS No: NA

Mol. F: C21H22N6O5

Mol. Wt: 438.44

Inv. Status: Custom Synthesis

N-Nitroso Trametinib Impurity 4

Cat. No: CL-TMTB-NO-04

CAS No: NA

Mol. F: C26H23FN6O5

Mol. Wt: 518.51

Inv. Status: Custom Synthesis

N-Nitroso Trametinib Impurity 5

Cat. No: CL-TMTB-NO-05

CAS No: NA

Mol. F: C17H16FIN4O4

Mol. Wt: 486.24

Inv. Status: Custom Synthesis

N-Nitroso Trametinib Impurity 6

Cat. No: CL-TMTB-NO-06

CAS No: NA

Mol. F: C26H22FIN6O5

Mol. Wt: 644.4

Inv. Status: Custom Synthesis

N-Nitroso Trametinib Impurity 7

Cat. No: CL-TMTB-NO-07

CAS No: NA

Mol. F: C24H20FIN6O4

Mol. Wt: 602.36

Inv. Status: Custom Synthesis

N-Nitroso Trametinib Impurity 8

Cat. No: CL-TMTB-NO-08

CAS No: NA

Mol. F: C14H12FIN4O3

Mol. Wt: 430.18

Inv. Status: Custom Synthesis

N-Nitroso Trametinib

Cat. No: CL-TMTB-NO-09

CAS No: NA

Mol. F: C26H22FIN6O5

Mol. Wt: 644.4

Inv. Status: Custom Synthesis